^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    GENE:

    LECT2 (Leukocyte Cell Derived Chemotaxin 2)

    i
    Other names: LECT2, Leukocyte Cell Derived Chemotaxin 2, Chm-II, Chm2, Leukocyte Cell-Derived Chemotaxin-2, Leukocyte Cell-Derived Chemotaxin 2, Chondromodulin-II, LECT-2, HLECT2
    Associations

    News

    Trials
    1year
    miR-328-3p suppresses hepatocellular carcinoma progression by regulating HMOX1 expression. (PubMed, Discov Oncol)
    Our study has advanced our understanding of the roles of miR-328-3p and HMOX1 in HCC, demonstrating the inhibitory effect of miR-328-3p on the oncogenic activity of HMOX1. Hence, these results revealed the function of miR-328-3p and a novel mechanistic pathway for HCC and suggested the potential therapeutic targeting of miR-328-3p and HMOX1 for HCC intervention strategies.
    Journal
    |
    BIRC5 (Baculoviral IAP repeat containing 5) • SPP1 (Secreted Phosphoprotein 1) • IGF1 (Insulin-like growth factor 1) • HMOX1 (Heme Oxygenase 1) • MIR328 (MicroRNA 328) • RBP2 (Retinol Binding Protein 2) • LECT2 (Leukocyte Cell Derived Chemotaxin 2)
    |
    HMOX1 expression • HMOX1 overexpression
    over1year
    Global research trends and hotspots for leukocyte cell-derived chemotaxin-2 from the past to 2023: a combined bibliometric review. (PubMed, Front Immunol)
    The current LECT2 research outcomes are not exceptional. We hope to promote the scientific research of LECT2 and exploit its potential for clinical diagnosis and treatment of related diseases through a comprehensive bibliometric review.
    Review • Journal
    |
    LECT2 (Leukocyte Cell Derived Chemotaxin 2)
    2years
    Loss of LECT2 promotes ovarian cancer progression by inducing cancer invasiveness and facilitating an immunosuppressive environment. (PubMed, Oncogene)
    The therapeutic efficacy of programmed cell death-1 (PD-1)/PD-L1 pathway blockade for the ID8 model was significantly hindered. Overall, our data highlight multiple functions of Lect2 during EOC progression and reveal a rationale for synergistic immunotherapeutic strategies by targeting Lect2.
    Journal
    |
    MET (MET proto-oncogene, receptor tyrosine kinase) • LECT2 (Leukocyte Cell Derived Chemotaxin 2)
    over2years
    EFFICACY OF RNAi-MEDIATED BETA-CATENIN INHIBITION IN MULTIPLE IMMUNOCOMPETENT MOUSE MODELS OF HEPATOCELLULAR CARCINOMA (AASLD 2023)
    Our studies demonstrated the efficacy of RNAi-mediated inhibition of CTNNB1 for β-catenin-mutated HCC and provide strong preclinical evidence to support clinical translation as monotherapy as well as in combination with other treatments.
    Preclinical • IO biomarker
    |
    CCND1 (Cyclin D1) • CTNNB1 (Catenin (cadherin-associated protein), beta 1) • GLUL (Glutamate-Ammonia Ligase) • LECT2 (Leukocyte Cell Derived Chemotaxin 2)